Biomarkers of Cognitive Decline Among Normal Individuals: The Biocard Cohort

总体--项目摘要/摘要 这是一项名为《正常人群中认知功能下降的生物标记物》基金的竞争延续 个人：BIOCARD队列‘(FOA：PAR-18-296)。这项研究被称为BIOCARD研究，是一项 349名认知正常且以中年为主的人的纵向观察研究 (平均年龄57.1岁)。根据设计，三分之二的人有阿尔茨海默病(AD)的家族史。这个 主要目标是跟踪个人从正常认知到轻度认知障碍(MCI)或痴呆症，因此 有可能确定预测疾病进展的生物标记物。BIOCARD的这项研究是在一个独特的 检查AD临床前阶段的职位，因为参与者：(1)已经被跟踪长达27年 年(平均随访=15.2年)，(2)持续风险加速期，(3) 那些活着的人患有MCI或痴呆症。我们的总体目标是进一步推进临床前研究 AD通过：(1)澄清AD生物标志物(包括基于脑脊液、血液、 MRI和PET成像)和认知；待研究的生物标记物包括几个有希望的新的 来自血液、脑脊液和脑成像的生物标志物。(2)通过与合作伙伴协作最大限度地利用数据 几个研究小组谁拥有可比较的数据，以及(3)提供公开可访问的数据，脑扫描， 和生物标本，供该领域的研究人员使用。队列的长期跟踪是基于 事实上，这项研究是由NIH内部项目的研究人员于1995年建立的。这项研究 于2005年因行政目的而被停止。我们的调查小组于2009年7月获得资助，重新登记 并重新启动纵向数据收集。在我们的资助下，继续进行纵向跟踪 2014年续签。通过这项申请，我们请求资金继续进行纵向评估， 包括：临床和认知评估、脑脊液、血液、核磁共振扫描和淀粉样蛋白PET(使用[11-C]PIB)和 在认知正常的参与者(n=198，平均)中启动Tau PET(使用[18 F]MK-6240) 年龄=70.9岁)。此外，我们亦建议增聘150名科目，以增加 参与者并扩大中年受试者的数量，这些受试者可以跟随最先进的- 技巧。将获得的丰富数据将为AD的临床前阶段提供持续的见解。

OVERALL – PROJECT SUMMARY/ABSTRACT This is a competing continuation for a grant entitled ‘Biomarkers of Cognitive Decline Among Normal Individuals: The BIOCARD Cohort’ (FOA: PAR-18-296). This study, known as the BIOCARD study, is a longitudinal, observational study of 349 individuals who were cognitively normal and primarily middle aged (mean age=57.1) at enrollment. By design, two-thirds had a family history of Alzheimer’s disease (AD). The primary goal was to follow individuals from normal cognition to mild cognitive impairment (MCI) or dementia, so that it would be possible to identify biomarkers that predicted progression. The BIOCARD study is in a unique position to examine the ‘preclinical’ phase of AD, since the participants: (1) have been followed for up to 27 years (mean follow-up = 15.2 yrs.), (2) are continuing through the period of accelerating risk, and (3) 64 of those alive have MCI or dementia. Our overall objectives are to further advance the study of preclinical AD by: (1) clarifying the pattern and rate of change in AD biomarkers (including those based on CSF, blood, MRI, and PET imaging) and cognition; the biomarkers to be studied include several promising novel biomarkers derived from blood, CSF and brain imaging. (2) maximizing our data by working collaboratively with several research groups who have comparable data, and (3) providing a publicly accessible data, brain scans, and biological specimens, for researchers in the field. The long duration of follow-up for the cohort is based on the fact that the study was established in 1995 by investigators in the intramural program of the NIH. The study was stopped for administrative purposes in 2005. Our investigative team was funded in July 2009 to re-enroll the participants and re-initiate longitudinal data collection. Longitudinal follow-up was continued with our grant renewal in 2014. With this application, we are requesting funds to continue the longitudinal assessments which include: clinical and cognitive assessments, CSF, blood, MRI scans, and amyloid PET (using [11-C] PiB) and to initiate Tau PET (using [18 F] MK-6240), in the participants who remain cognitively normal (n=198, mean age = 70.9). We are also proposing to recruit an additional 150 subjects to increase the diversity of the participants and to expand the number of middle age subjects who can be followed with state-of-art- techniques. The rich data to be acquired will provide continued insights into the preclinical phase of AD.